Physician profile
Hetal Gor
NPI 1003911280
$1,657.25
in general payments reported to CMS, 2019-2025
13 companies · $75.88 in 2025
The $75.88 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $562 · 2020: $179 · 2021: $181 · 2022: $19.00 · 2023: $366 · 2024: $274 · 2025: $75.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $716.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $699.17 | 2019-2025 | Watchman Flx |
| Abbvie INC. | $205.96 | 2019-2021 | |
| Avion Pharmaceuticals | $187.37 | 2019-2022 | |
| Amarin Pharma, INC. | $125.00 | 2019 | |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $90.32 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $89.16 | 2021 | |
| Roche Diagnostics Corporation | $57.12 | 2019 | |
| Amgen INC. | $26.08 | 2021-2023 | Prolia, Evenity |
| Meditrina | $13.91 | 2021 | |
| Exeltis, USA INC. | $13.88 | 2019 | |
| Allergan, INC. | $12.42 | 2019 | |
| Dysis Medical, INC. | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hetal Gor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.